anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To provide a technique for managing the state of diseases by an ophthalmology inspection device set in the house of a patient, for example.SOLUTION: In the patient management system according to an embodiment, an ophthalmology inspection device is connected to a cloud server by a communication line and generates inspection data for target eyes. Each server in medical facilities is connected to a cloud server by a communication line. The ophthalmology inspection device sends the inspection data for the target eyes to the cloud server. The cloud server receives the inspection data sent from the ophthalmology inspection device and analyzes the inspection data. When an abnormality is found as a result of the analysis, the cloud server sends information of the target eyes to one of the servers in the medical facilities. The cloud server further introduces the patient to a medical facility equipped with at least one of the servers in the medical facilities.SELECTED DRAWING: Figure 1
A. Randomization of subjects: Infants will be randomized to receive Proparacaine versus no intervention based on computerized randomization performed by our statistician. Due to the lack of a placebo group, practitioners present at the time of examination will not able to be blinded to group assignment. Each infant will only be enrolled for one examination.

B. Monitor setup/application: The Central Nervous System (CNS) Neonatal Neurological Monitor (Moberg Research) will be used to videotape each patient encounter and record vital sign information during the study period. The CNS monitor will record physiologic variables indirectly via cables attached to the bedside monitor. Before scheduled eye drop administration takes place, the appropriate connections between the bedside monitor and CNS monitor will be made in order to continuously record heart rate, respiratory rate, pulse oximetry, and blood pressure. A video camera attached to the CNS monitor will also be positioned to capture the subjects' facial activity and gross body movements. The monitor will be set up with enough time prior to eye drop administration such that baseline data can be collected before any intervention is performed. In addition, a video recording of the method of eyedrop administration will be assessed. The monitor will remain in place up to 5 minutes after completion of eye drop administration.

C. Eye drop administration: The CNS Monitor will be in place at least 3 minutes prior to administration of any eye drops to record baseline data on the infant. One drop of Proparacaine anesthetic ophthalmic solution will be applied to each eye of infants randomized to receive Proparacaine prior to the mydriatic eye drops. At least 30 seconds and no longer than 5 minutes after administration of Proparacaine, the mydriatic eye drops will be given as per routine standard practice for ophthalmologic examinations in the NICU.
FIELD: medicine, cardiology, clinical medicine. SUBSTANCE: method involves additional prescription of polyene in the dose 3.6 g per 24 h for 2 intakes: in morning and evening for 28-30 days to patients with ischemia heart disease dosing with nitro-preparations, inhibitors of angiotensin - transforming ferments, β-antagonists and aspirin. Invention can be used for prophylaxis and recovery of cardiac rhythm in patients with ischemic heart disease. Method provides normalization of cardiac rhythm due to recovery of indices of rhythm variability and later potential values of ventricles of heart. EFFECT: enhanced effectiveness of prophylaxis and recovery. 8 tbl
The present invention relates to a skin external application composition comprising an extract of a Glycyrrhiza uralensis and Paeonia lactiflora mixture as an active ingredient to relieve stimulation and inflammation of skin and, more specifically, to a composition capable of relieving skin stimulation due to various external toxic substances, and inhibiting inflammation by further including one or more medical herb extracts selected from Paeonia lactiflora, Angelica gigas, Rheum palmatum, Aralia continentalis, Angelica dahurica, Lycopus lucidus, Schizonepeta tenuifolia, and Phellodendron amurense in the Glycyrrhiza uralensis and Paeonia lactiflora mixture. According to an embodiment of the present invention, the skin external application composition minimizes side effects by using a natural extract; detoxifies and discharges toxins by increasing expression of NQO1, which detoxifies external toxins, and GSTT1 which discharges the toxins; and protects skin by increasing expression of hBD3 which is a natural immunity factor. The skin external application composition relieves the skin stimulation and the inflammation by inhibiting IL-6, IL-8, TNF-, etc. which are cytokines generated by ultraviolet rays and inhibiting yellow dust, heavy metal included in the yellow dust, and NO due to air pollution substances. According to the present invention, the skin external application composition has an excellent antioxidant effect. Therefore, the skin external application composition can be variously applied to cosmetics industry.
The number of patients with oesophageal cancer is rising dramatically in the UK. Curative cancer surgery (oesophagectomy) is offered to around 40% of affected patients. However, oesophagectomy is a major operation with a high risk of complications. Around 1 in 3 patients will suffer such a complication after surgery, mostly due to heart or lung problems. Most complications are not due to the surgery itself, but related to the patient's physical fitness before their operation. Studies in other surgeries, but not oesophagectomy, have shown that complications may be reduced by improving a patient's physical fitness before their operation. The ExPO team has developed a pre-operative Personalised Exercise Programme (my-PEP), specifically for patients undergoing oesophagectomy. my-PEP has 4 main components: three are exercise modalities (aerobic exercise, breathing exercises and muscle strengthening); the fourth is where a participant's potential barriers to exercise are assessed and behavioural change techniques (BCTs) are suggested to improve exercise engagement in the trial. In total, 32 patients who are due to undergo oesophagectomy at the Norfolk and Norwich Hospital will be recruited and then randomly divided into 2 arms of 16 each. One arm will receive my-PEP in the standard 3-4 months prior to surgery, the other will receive standard care advice to exercise at home. The research objectives are to obtain feasibility data on whether my-PEP is acceptable, adhered to and safe, and whether it improves patient fitness above standard care. Follow up will be 90 days after surgery to obtain a preliminary imprecise estimate of whether my-PEP reduces complications. If the ExPO trial shows promise in these areas, this will inform and justify a future large multi-centre trial to definitively answer whether my-PEP can reduce complications after oesophagectomy. If so, my-PEP could potentially change and improve the pre-operative management of oesophageal cancer patients across the NHS.
PURPOSE:To obtain percutaneous absorbing preparation useful for various medical treatments effectively making skin to absorb drug in safety without skin irritation, containing specific gallic acid alkyl ester as absorption accelerator. CONSTITUTION:Gallic acid alkyl ester expressed by the formula (R is 1-18C alkyl) is contained in the aimed preparation as drug (e.g. antipyretic analgesics and antiphlogistic such as indomethacin or salicylic acid, or steroid-based antiphlogistic such as hydrocortisone) and absorption-accelerator of said drug. Contained fraction of the compound expressed by the formula in the preparation is 0.5-30wt.%. The percutaneous absorbing preparation is used in various styles such as tape preparation, patching agent or cataplasm. On one face of support of tape preparation or patching agent, tacky agent layer containing drug and absorption accelerator (butyl acrylate, etc., as tacky agent) is formed.
Proposed method rejuvenation consists in intravenous injection of a new bacterial collagenolytic agent to replace aged collagen to young more permeable collagen in entire organism with renewal the young condition for the cells' functions. Collagen - the principal protein of connective tissue is extra-cellular. With aging collagen becomes denser and its permeability decreases. The replacement of old collagen to young collagen by proposed method results in acceleration of interstitial fluid circulation in connective tissue. It improves the supply of the cells with nutrients, hormones and other biological active compounds and removal of metabolism products. Events involved therewith may be defined as the rejuvenation.
Myocardial ischemia-reperfusion injury (MIRI) poses a significant threat to patients with coronary heart disease. Adenosine A2A receptors have been known as a protective role in MIRI by regulating autophagy, so we assumed that activation of adenosine A2B receptor (A2BAR) might exert a similar effect during MIRI and underlying mechanism be related to proteostasis maintenance as well. In situ hearts were subjected to 30 min of ischemia and 120 min of reperfusion (IR), while invitro cardiomyocytes from neonatal rats experienced 6 h of oxygen-glucose deprivation followed by 12 h of reoxygenation (OGDR). Initially, we observed that post-ischemia-reperfusion induced autophagy flux blockade and ERS both in vivo and in vitro, evident through the increased expression of p62, LC3II, and BIP, which indicated the deteriorated proteostasis. We used a selective A2BAR agonist, Bay 60-6583, to explore the positive effects of A2BAR on cardiomyocytes and found that A2BAR activation rescued damaged cardiac function and morphological changes in the IR group and improved frail cell viability in the OGDR group. The A2BAR agonist also alleviated the blockage of autophagic flux, coupled with augmented ERS in the IR/OGDR group, which was reassured by using an autophagy inhibitor chloroquine (CQ) and ERS inhibitor (4-PBA) in vitro. Additionally, considering cAMP/PKA as a well-known downstream effector of A2BAR, we utilized H89, a selective PKA inhibitor. We observed that the positive efficacy of Bay 60-6583 was inhibited by H89. Collectively, our findings demonstrate that the A2BAR/cAMP/PKA signaling pathway exerts a protective role in MIRI by mitigating impaired autophagic flux and excessive ERS.
The invention aims to provide a traditional Chinese medicinal formula for enhancing body immunity of chickens, promoting digestion, killing bacteria and pests, clearing heat and removing toxin, and eliminating inflammation and fortifying stomach. In the traditional Chinese medicinal formula, agrimonia pilosa, honeysuckle, astragalus membranaceus, hawthorn, radix isatidis, sophora flavescens, radix glycyrrhizae are mixed together and are crushed, or are respectively crushed and are mixed together. The traditional Chinese medicine is mixed according to a proportion of 0.5-0.10% with a chicken feed. The feed can be fed for chicken in young period. The traditional Chinese medicinal formula is free of any toxic and side effects. The raw materials are easy to obtain and low in cost. The traditional Chinese medicine, when being mixed with daily feed for feeding the chicken, has excellent preventing and treating effects on common diseases of chickens, such as avian influenza, white diarrhea, cholera, escherichia coli, ascariasis and the like.
The invention provides a transient fluorescent tint for entertainment, and belongs to the technical field of daily cosmetics. The tint comprises a first agent and a second agent. The first agent is prepared from, by weight, 10-15 of 5% mercaptoacetic acid solution, 5-7 of sodium carboxymethylcellulose and 70-100 of water. The second agent is prepared from, by weight, 20-24 of NBD-C1, 10-12 of sodium carboxymethylcellulose, 2-3 of citric acid, 2-3 of glycerinum, 1-2 of perfume and 60-70 of water. The first agent has main effects on returning cystine in hair keratin and making an -S-S- key break to form an -SH key; the second agent has main effects on making sulfydryl (-SH) generated under the effects of NBD-C1 and the first agent react to generate fluorescent light. The transient fluorescent tint has the advantages that dyeing is easy, color fading is mild, the color can fade at any time, and harms to hair are small.
Several studies have demonstrated the efficacy and safety of combining an individual LABA compound plus an individual LAMA compound in COPD. These studies have shown the combination of these two products to be superior to either agent alone on a variety of outcomes in COPD. The beneficial effects of this combination regimen are likely due to the different mechanisms of action of the two bronchodilators (smooth bronchial muscle relaxation from activation of beta2 receptors from the LABA product and inhibition of acetylcholine-mediated smooth bronchial muscle contraction via blockade of muscarinic receptors from the LAMA product). The availability of a LABA/LAMA combination in one product instead of two individual products is a technical and therapeutic advancement in the pharmacological armamentarium for COPD and may lead to increased patient compliance due to once-daily administration. The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication, and lung function) of GSK573719/GW642444 Inhalation Powder 125/25mcg in subjects with COPD. The long-term safety of GSK573719 Inhalation Powder 125mcg will also be evaluated. A placebo arm is included to evaluate these products compared to an inactive control. All treatments will be delivered once-daily via the nDPI. This study will establish the long-term safety profile of GSK573719/GW642444 Inhalation Powder 125/25mcg once-daily in subjects with COPD. The safety profile of GSK573719 Inhalation Powder125mcg once-daily will also be evaluated.
INTRODUCTION: Surveillance modernization efforts emphasize the potential use of electronic health record (EHR) data to inform public health surveillance and prevention. However, EHR data streams vary widely in their completeness, accuracy, and representativeness.
METHODS: We developed a validation process for the Multi-State EHR-Based Network for Disease Surveillance (MENDS) pilot project to identify and resolve data quality issues that could affect chronic disease prevalence estimates. We examined MENDS validation processes from December 2020 through August 2023 across 5 data-contributing organizations and outlined steps to resolve data quality issues.
RESULTS: We identified gaps in the EHR databases of data contributors and in the processes to extract, map, integrate, and analyze their EHR data. Examples of source-data problems included missing data on race and ethnicity and zip codes. Examples of data processing problems included duplicate or missing patient records, lower-than-expected volumes of data, use of multiple fields for a single data type, and implausible values.
CONCLUSION: Validation protocols identified critical errors in both EHR source data and in the processes used to transform these data for analysis. Our experience highlights the value and importance of data validation to improve data quality and the accuracy of surveillance estimates that use EHR data. The validation process and lessons learned can be applied broadly to other EHR-based surveillance efforts.
A medication dispensing device and method that forces patient compliance with a health-care-provider-prescribed medication schedule. The device may be filled with medication by a health care provider, but not by the patient. The device may be programmed to limit access to medication with prescribed minimum time intervals between access to doses. These minimum time intervals may be uniform or flexible. The device may unlock to grant a patient access to a dose of medication through a lock. The device may also be programmed to prevent any release of medication after a prescribed period of time has elapsed. The device may include an insert to prevent cross contamination between uses. The device may include an unlocked compartment housing limited amounts of medication to be accessed as needed. The device may be returned to a health care provider to dispose of excess medication.
Participants of syringe exchange programs routinely suffer from untreated or under-treated substance use disorder, a situation that is associated with significant individual and public health costs. These individuals are also routinely embedded within social networks that reinforce continued drug use and related HIV-risk behaviors. The welfare of these individuals and the public's health can be improved by interventions directed toward reducing drug use risks and expanding drug-free support . Previous work by the investigators has demonstrated that an intervention combining an HIV risk reduction/treatment readiness group with behavioral contingencies is highly associated with increased rates of treatment enrollment and re-engagement, and reduced rates of drug use and HIV-injection risks, for up to one year. This protocol extends this work by adding a new component to the HIV risk reduction/treatment readiness group designed to expand social support and facilitate social network change. This intervention requires syringe exchange registrants to attend the group with a drug-free family or friend from their personal network that can provide stable support and encourage harm reduction and treatment seeking. This intervention uses an alteration network change model and posits that repeated exposure to drug-free community support collaterally reduces exposure to network members that support risk behaviors. This model also provides a pathway to modifying existing social networks by facilitating interaction with the personal social networks of drug-free family and friends. The intervention is supported by research showing that substance users report substantial pockets of drug-free family or friends in their social networks. It is also supported by community reinforcement principles that have shown efficacy in treatment samples, but have not been applied to out-of-treatment drug users. The present study has four primary aims. The first is to characterize natural drug-free support in the social networks of syringe exchangers. The second is to develop a Community Supported Risk Reduction group for syringe exchange participants and their community support. This group teaches skills for HIV risk reduction, treatment seeking, and healthy network expansion. The third and fourth aims are to obtain new data on the feasibility and efficacy of this intervention. Primary outcomes include changes in: 1) perceived social support, and 2) HIV risk behaviors.
SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
An apparatus includes a processor and a non-transitory memory. The processor is configured to receive pre-operative patient specific data. The pre-operative patient specific data is inputted to a first machine learning model to determine a first predicted post-operative joint performance data output including first predicted post-operative outcome metrics. A reconstruction plan of the joint of the patient is generated based on a medical image of the joint, and at least one arthroplasty surgical parameter obtained from the user. The at least one arthroplasty surgical parameter is inputted into a second machine learning model to determine a second predicted post-operative joint performance data output including second predicted post-operative outcome metrics. The second predicted post-operative joint performance data output is updated to include an arthroplasty surgery recommendation, in response to the user varying the at least one arthroplasty surgical parameter, before the arthroplasty surgery, during the arthroplasty surgery, or both.
We will enroll patients who have undergone cardiac transplantation into a randomized, double-blind, 12-month study of the efficacy and safety of calcitriol (Rocaltrol) and alendronate sodium (Fosamax) in the prevention of bone loss after transplantation. We will give all participants standard pre- and post-transplantation management and immunosuppressive therapy, three tablets of calcium citrate (Citracal + D, each containing 315 mg of elemental calcium and 200 IU of vitamin D), and a multivitamin providing 400 units of vitamin D daily. We will randomize participants to one of two active treatment groups within 1 month of transplantation. We will give Group A active alendronate (10 mg/day) and placebo calcitriol. We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID). The primary efficacy endpoint is the change in spine bone mineral density (BMD) during the first 6 months after transplantation. The secondary efficacy endpoint is the change in hip BMD during the first year after transplantation. We will also monitor the incidence of vertebral fracture.

We will invite eligible subjects to participate in the study. We will offer patients who elect not to participate in the therapeutic trial the opportunity to have serial BMD measurements at the same intervals as treated subjects and to be followed as untreated controls. We will continue recruitment until we have randomized a total of 146 cardiac transplant recipients. We will perform bone densitometry at randomization (unless performed within the previous month) and at 6 and 12 months. We will obtain radiographs (x-rays) at randomization and will repeat them at 12 months to detect undiagnosed vertebral fractures.
BACKGROUND: Fatigue has been observed after the outbreaks of several infectious diseases around the world. To explore the fatigue level among physicians working in COVID-19-designated hospitals in Bangladesh, a matched case‒control study was conducted on post-SARS-CoV-2 fatigue.
METHOD: In this study, 105 physicians diagnosed with COVID-19 who were declared cured at least 6 weeks before the interview date were recruited as cases, and the same number of age- and designation-matched healthy physicians were recruited as controls from the same hospital at a 1:1 ratio. Diagnosis of COVID-19 infection was confirmed by detection of SARS CoV-2 antigen by RT‒PCR from reference laboratories in Bangladesh or by HRCT chest.
RESULT: Approximately two-thirds of the physicians were male (67.6% vs. 32.4%). More than 80% of them were younger than 40 years. The cases had a significantly greater number of comorbid conditions. The fatigue severity scale (FSS) score (mean) was much higher for cases (36.7 ± 5.3 vs. 19.3 ± 3.8) than for the control group, with a statistically significant difference. Similarly, approximately 67.7% of the previously COVID-19-positive physicians were in the highest FSS score tertile compared to the respondents in the control group, who had a mean score of <3.
CONCLUSION: Physicians who had a previous history of COVID-19 infection had significantly higher total and mean FSS scores, signifying a more severe level of fatigue than physicians who had never been COVID-19 positive while working in the same hospital irrespective of their age and sex.